Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a powerful GLP-1 receptor agonist that has helped millions achieve significant weight loss, but it carries important safety restrictions that rule it out for specific patient populations. Understanding these contraindications is essential before pursuing compounded semaglutide therapy from a licensed provider.

Personal or Family History of Thyroid Cancer

Semaglutide carries a boxed warning for patients with a personal or family history of medullary thyroid carcinoma (MTC), a rare but aggressive form of thyroid cancer. Animal studies demonstrated that GLP-1 agonists can trigger C-cell tumors in the thyroid gland, raising serious safety concerns in high-risk populations. Patients with this cancer history or a family predisposition to MTC should not use semaglutide under any circumstances.

Additionally, individuals with a diagnosis of multiple endocrine neoplasia type 2 (MEN2) syndrome are absolutely contraindicated from semaglutide use. MEN2 substantially elevates thyroid cancer risk, and GLP-1 medications may accelerate tumor growth. Any patient with these conditions should discuss alternative weight loss strategies with their healthcare provider before considering any GLP-1 therapy.

Severe Gastrointestinal Disorders and Pancreatitis History

Patients with severe diabetic retinopathy or a history of acute pancreatitis should avoid semaglutide, as GLP-1 agonists can worsen retinal damage and trigger pancreatitis recurrence. Pancreatitis—inflammation of the pancreas—can be life-threatening, and semaglutide may increase risk in susceptible individuals. Those with inflammatory bowel disease, gastroparesis, or chronic intestinal obstruction also face elevated risk of serious complications because semaglutide slows gastric emptying.

Severe gastrointestinal conditions like Crohn's disease or ulcerative colitis may be exacerbated by semaglutide's effects on gut motility and satiety signaling. Patients who have experienced previous episodes of acute pancreatitis, even if unrelated to medication, require thorough evaluation before any GLP-1 compound is prescribed. A comprehensive medical history and imaging assessment should guide this decision.

Pregnancy, Breastfeeding, and Thyroid Dysfunction

Semaglutide is contraindicated in pregnancy and during breastfeeding because adequate safety data in these populations does not exist. GLP-1 agonists may affect fetal development and metabolic pathways critical to pregnancy, making them unsuitable for women planning conception or currently pregnant. Women of childbearing age should use reliable contraception while on semaglutide and notify their healthcare provider immediately if pregnancy is confirmed.

Patients with pre-existing thyroid disease, including hypothyroidism or hyperthyroidism, require careful evaluation before starting semaglutide. While semaglutide itself does not directly cause thyroid dysfunction, it can alter thyroid hormone levels and medication absorption, potentially destabilizing patients on thyroid replacement therapy. Those with uncontrolled thyroid conditions should achieve euthyroid status before considering GLP-1 weight loss therapy.

Certain Medication Interactions and Kidney Disease

Semaglutide interacts significantly with medications that slow gastric emptying, such as some diabetes drugs and certain antiemetics, potentially amplifying side effects or reducing drug efficacy. Patients taking other GLP-1 agonists or incretin-based diabetes medications should not combine these with semaglutide due to additive hypoglycemic risk. Additionally, those on warfarin or other anticoagulants may experience altered blood clotting due to semaglutide's effects on intestinal absorption and weight loss-related changes in drug distribution.

Individuals with severe chronic kidney disease (eGFR below 15 mL/min/1.73m²) or those on dialysis face potential risks from semaglutide because GLP-1 effects on renal perfusion and fluid balance are not fully characterized in end-stage renal disease. Moderate kidney disease may allow semaglutide use with close monitoring, but severe renal impairment warrants avoidance. Patients with diabetes-related kidney damage should discuss semaglutide safety with their nephrologist before initiating therapy.

How PlexusDx Ensures Safe Medication Selection

PlexusDx works with licensed 503A compounding pharmacies and requires comprehensive medical screening before prescribing compounded semaglutide injection starting at $149 per month. Every patient undergoes a thorough health history review, medication interaction check, and clinical evaluation to identify contraindications early. If semaglutide is not appropriate, PlexusDx providers can recommend alternative GLP-1 compounds like compounded tirzepatide injection or oral formulations tailored to individual safety profiles.

The Precision Peptide Genetic Test, available as a $99 add-on after the first month of treatment, maps 14 metabolic pathways and 150+ genetic insights to optimize medication selection and dosing strategy. This genetic analysis examines peptide-pathway variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—markers that influence how individuals respond to GLP-1 therapy. PlexusDx's personalized approach ensures that only patients who can safely tolerate semaglutide proceed with treatment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take semaglutide if I have diabetes?

Semaglutide is approved for type 2 diabetes management, but patients with type 1 diabetes should not use it. Those with diabetes-related kidney disease or severe retinopathy need medical evaluation before starting. PlexusDx providers conduct thorough diabetes assessments before prescribing compounded semaglutide injection or alternatives.

What happens if I have a history of gallbladder problems?

Rapid weight loss from semaglutide can increase gallstone formation risk, particularly in patients with pre-existing gallbladder disease. While semaglutide itself does not directly cause gallstones, those with cholelithiasis or biliary colic history should discuss benefits and risks with their provider before starting therapy. Close monitoring and gradual dosing may be necessary.

Is compounded semaglutide from PlexusDx safe if I cannot afford brand-name versions?

Yes. PlexusDx compounded semaglutide injection starts at $149 per month from licensed 503A compounding pharmacies, with no insurance required, no membership fee, and HSA/FSA eligibility. Safety standards match pharmaceutical-grade medications because all compounds are prepared by licensed pharmacies following strict quality guidelines.

Can I take semaglutide with blood pressure or heart medications?

Most blood pressure and cardiac medications do not directly contraindicate semaglutide, but semaglutide-induced weight loss may require adjustment of dosages for hypertension or heart failure drugs. Medications affecting heart rate or blood glucose may interact. PlexusDx providers review all medications during the screening process to identify potential interactions.

Does the Precision Peptide Genetic Test predict who cannot take semaglutide?

The Precision Peptide Genetic Test identifies how your body metabolizes GLP-1 agonists based on 14 pathways and 150+ genetic insights, helping determine if semaglutide or an alternative like tirzepatide is optimal. While it does not replace medical screening for contraindications, it personalizes medication selection to maximize safety and efficacy after clinical clearance is confirmed.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves